Journal
AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS
Volume 10, Issue 4, Pages 257-261Publisher
TAYLOR & FRANCIS LTD
DOI: 10.3109/13506120309041743
Keywords
amyloidosis; thalidomide; multiple myeloma; toxicity
Categories
Funding
- NCI NIH HHS [CA 91561] Funding Source: Medline
Ask authors/readers for more resources
Treatments effective against multiple myeloma may be useful in primary systemic amyloidosis (AL). Thalidomide is active in myeloma. Results of the first 12 patients enrolled on aphase II trial of thalidomide for AL are presented. Progressive edema, cognitive difficulties, and constipation occurred in approximately 75%; dyspnea, dizziness and rash in 50%. Five developed progressive renal insufficiency. Deep venous thrombosis and syncope each occurred in two. Median time on the study was 72 days, range was 25 to 333 days. All 12 have withdrawn from the study (side-effects, 6; progression, 4; and death, 2 patients). AL patients do not tolerate high dose thalidomide.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available